Ticker NEXR has barely 550,000 shares outstanding.
The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$.
NEXR released news on Aug 3rd and is shifting heavily into the AI sector.
NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon.
$ATXG $ATXI might trend
$ATXI $FBIO
Clenbuterol ATX-04
Pompe disease is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to toxic glycogen buildup, severe muscle weakness, and respiratory/heart issues. It affects approximately 1 in 40,000 people and has infantile-onset (severe) and late-onset forms.Key Aspects of Pompe Disease:Causes: It is an autosomal recessive disorder caused by mutations in the GAA gene, meaning a child must inherit two faulty genes (one from each parent) to develop the disease.
$FBIO the stock is still 33% higher YoY. Given the governance, the debt, the unresolved dividends payment and the total disaster of many subsidiaries like $MBIO and $ATXI plus the disappointing revenue of $DERM , not to mention the ongoing dilution with B. $RILY as ATM agent, I consider this still overpriced.
Investing $3,000 in $ATXI last year would be worth approx $100,000 today.
This is the kind of return I love to see and is always an investors dream.
All you need is due diligence. Stop it with the negative mindset and make it happen.
